Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01728493
Other study ID # 40133.091.12
Secondary ID
Status Completed
Phase N/A
First received November 13, 2012
Last updated April 5, 2016
Start date September 2013
Est. completion date February 2016

Study information

Verified date April 2016
Source Radboud University
Contact n/a
Is FDA regulated No
Health authority Netherlands: Medical Ethics Review Committee (METC)
Study type Observational

Clinical Trial Summary

Primary aldosteronism (PA) is the most frequent form of secondary hypertension. It is caused by autonomous secretion of aldosterone, encompassing a group of disorders which is for 99% predominated by unilateral aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia (BAH). Diagnosis of PA is relevant for two reasons:

1. independent of the level of blood pressure, hypertension due to autonomous aldosterone secretion causes more cardiovascular damage than essential hypertension;

2. PA requires specific treatment: adrenalectomy in case of APA and mineralocorticoid receptor antagonists (MRA) in case of BAH.

Although previously presumed a rare condition (prevalence <1%), PA is now estimated to affect 6 to 20% of the hypertensive population. Given this high prevalence of PA, as well as the amount of cardiovascular damage and the available specific treatment, the question is raised whether screening of PA should be introduced in Dutch general practice. To answer this important question, several issues with regard to PA need to be elucidated:

1. International studies report a prevalence of PA in general practice of 6-13%. Prevalence in the Dutch population is still unknown;

2. Because of underdiagnosis of PA and long delay in diagnosis of PA after recognition of hypertension (mean eight years), data on characteristics of early diagnosed PA are lacking. Proof of early cardiovascular damage would strengthen the case of screening for PA and needs to be studied;

3. Consequently, the diagnostic delay has lead to lack of data on optimal treatment in early PA. In the current guideline (NHG-guideline 'Cardiovascular risk management') a regimen of antihypertensive drugs is advised, and only if hypertension is refractory for >6 months patients are referred. It is unknown if hypertension is resistant to therapy in the initial phase of PA. If not, this would also argue for early biochemical screening for PA, because even if blood pressure is controlled, the detrimental effect of aldosterone itself will go on unopposed. It is therefore required to study the response to antihypertensive drugs (not MRA) in these patients.


Description:

Rationale: Primary aldosteronism (PA) is the most frequent form of secondary hypertension. It is caused by autonomous secretion of aldosterone, encompassing a group of disorders which is for more than 99% predominated by unilateral aldosterone-producing adenoma (APA) and bilateral adrenal hyperplasia (BAH). Diagnosis of PA is relevant for two reasons: 1) independent of the level of blood pressure, hypertension due to autonomous aldosterone secretion causes more cardiovascular damage than essential hypertension; 2) PA requires specific treatment: adrenalectomy in case of APA and mineralocorticoid receptor antagonists (MRA) in case of BAH.

Although previously presumed a rare condition (prevalence <1%), PA is now estimated to affect 6 to 20% of the hypertensive population. Given this high prevalence of PA, as well as the amount of cardiovascular damage and the available specific treatment, the question has been raised whether screening of PA should be introduced in Dutch general practice. To answer this important question, several issues with regard to PA need to be elucidated:

1. International studies report a prevalence of PA in general practice of 6-13%. Prevalence in the Dutch population is still unknown;

2. Up to now, the laboratory test for screening for PA, the aldosterone/renin ratio (ARR), is primarily used in secondary care. The relation between the ARR and outcomes in primary care is unknown;

3. Because of underdiagnosis of PA and long delay in diagnosis of PA after recognition of hypertension (mean eight years), data on characteristics of early diagnosed PA are lacking. Indications of early cardiovascular damage would strengthen the case of screening for PA and needs to be studied.


Recruitment information / eligibility

Status Completed
Enrollment 700
Est. completion date February 2016
Est. primary completion date December 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

Part 1:

1. Newly diagnosed hypertensive patients (according to the NHG-guideline 'Cardiovascular risk management');

2. 18 years or older;

3. No use of antihypertensive medication.

Part 2:

1. Patients with increased aldosterone/renin ratio;

2. Positive sodium loading test;

3. Written informed consent.

Part 2 + 3:

1. Patients with normal aldosterone/renin ratio;

2. Normal ARR;

3. Written informed consent.

Part 3:

1. Patients with increased aldosterone/renin ratio;

2. Positive sodium loading test;

3. Normokalemic;

4. Written informed consent.

Exclusion Criteria:

1. Use of antihypertensive medication;

2. Heart failure class II, III or IV (according to the New York Heart Association);

3. Pregnancy or breastfeeding.

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Locations

Country Name City State
Netherlands Radboud university medical center Nijmegen Gelderland

Sponsors (1)

Lead Sponsor Collaborator
Radboud University

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Other PAGODE part 2: organ damage To observe differences between newly diagnosed hypertensive patients with versus without primary aldosteronism in:
Serum sodium;
Serum glucose;
Diastolic blood pressure.
4 weeks No
Other PAGODE part 3: blood pressure regulation To observe differences between newly diagnosed hypertensive patients with versus without primary aldosteronism in:
Reduction in 24 hour ABPM using conventional antihypertensive medication;
Reduction in 24 hour ABPM using mineralocorticoid receptor antagonists.
4 months No
Primary PAGODE part 1: prevalence Prevalence of primary aldosteronism in newly diagnosed hypertensive patients in Dutch general practice. 4 months No
Primary PAGODE part 2: organ damage Difference in cardiorenovascular damage in patients with versus without primary aldosteronism, based on a composite of the following parameters:
Left ventricular mass index in g/m2;
Intima-media thickness of carotid artery in mm;
Pulse wave velocity in m/s;
Central aortic blood pressure in mmHg;
Flow-mediated dilation in %;
Albuminuria in mg albumin per mmol creatinin.
4 weeks No
Primary PAGODE part 3: blood pressure regulation Difference in reduction of daytime systolic ambulatory blood pressure measurement (ABPM) in patients with normokalemic primary aldosteronism versus patients with essential hypertension in a standardized treatment regimen during conventional antihypertensive therapy. 4 months No
Secondary PAGODE part 2: organ damage To observe differences between newly diagnosed hypertensive patients with versus without primary aldosteronism in:
Serum potassium;
Low density lipoprotein;
Total cholesterol to high density lipoprotein ratio.
4 weeks No
Secondary PAGODE part 3: blood pressure regulation To observe differences between newly diagnosed hypertensive patients with versus without primary aldosteronism in:
Reduction of daytime systolic ABPM in patients with primary aldosteronism versus patients with essential hypertension in a standardized treatment regimen during spironolactone (or eplerenone);
Serum potassium response using conventional antihypertensive medication;
Adverse effects using conventional antihypertensive medication;
Serum potassium response using spironolactone (or eplerenone);
Adverse effects using spironolactone (or eplerenone).
4 months No
See also
  Status Clinical Trial Phase
Completed NCT02885662 - Study of CS-3150 in Patients With Primary Aldosteronism N/A
Withdrawn NCT02096939 - Microvascular Function in Primary Aldosteronism N/A
Recruiting NCT06228677 - Comparison of Catecholamine Concentrations in Venous Blood During Selective Adrenal Artery Embolization
Recruiting NCT06047912 - Screening for Primary Aldosteronism in Hypertension With 24-hour URinary aLdosterone
Recruiting NCT04991961 - Effect of Anti-hypertensive Medications on the Diagnostic Accuracy in Screening for Primary Aldosteronism
Recruiting NCT05405101 - Randomised Trial Comparing Thermal Ablation With Adrenalectomy in the Treatment of Unilateral Asymmetric PA N/A
Recruiting NCT05501080 - The Effect of SAAE on Ventricular Remodeling in PA Patients N/A
Recruiting NCT05973604 - Prevalence of Primary Aldosteronism in Atrial Fibrillation
Recruiting NCT05826080 - Effect of Adrenocorticotropic Hormone Stimulation During Adrenal Vein Sampling in Primary Aldosteronism
Completed NCT04179019 - Calcium Channel Blockade in Primary Aldosteronism Phase 2
Completed NCT03500120 - Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism
Recruiting NCT04213963 - Prospective Study on Primary Aldosteronism in Resistant Hypertension
Completed NCT05435703 - Renal Cysts and Primary Aldosteronism
Recruiting NCT02945904 - IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism
Enrolling by invitation NCT02257450 - Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study N/A
Recruiting NCT05561361 - The Effect of SAAE on Vascular Endothelial Function in PA Patients
Completed NCT03398785 - Adrenal Artery Ablation Treats Primary Aldosteronism Phase 3
Recruiting NCT04428827 - Outcome of Patients With Primary Aldosteronism
Recruiting NCT03224312 - Chongqing Primary Aldosteronism Study
Completed NCT02756754 - Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism N/A

External Links